Edward A. Sausville, M.D., Ph.D., Associate Director for Clinical Research at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, has been named an Editor in Chief of the journal Cancer Chemotherapy and Pharmacology. Dr. Sausville, a nationally known cancer researcher and professor of medicine at the University of Maryland School of Medicine, has been a key member of the leadership team at the Greenebaum Cancer Center since 2004. Previously, he served as associate director of the National Cancer Institute’s Developmental Therapeutics Program.
Dr. Sausville succeeds Merrill J. Egorin, M.D., of the University of Pittsburgh Cancer Institute, who was an Editor in Chief of Cancer Chemotherapy and Pharmacology for more than 20 years. A highly respected cancer researcher who had helped to establish the Greenebaum Cancer Center, Dr. Egorin died Aug. 7, 2010, of multiple myeloma.
“I am honored and humbled to be selected to continue Dr. Egorin’s work at the journal. He was not only an outstanding scientist and clinician, but a fair and thoughtful editor who wanted to ensure that information that would benefit cancer patients was published as quickly as possible,” Dr. Sausville says.
E. Albert Reece, M.D., Ph.D., M.B.A., vice president of medical affairs at the University of Maryland and dean of the University of Maryland School of Medicine, says, “Ed Sausville has had a long distinguished career as a physician-researcher, with particular expertise in the field of new drug development, and brings a wealth of knowledge to his new position. I congratulate him on being named an editor in chief of this well-respected journal.”
Dr. Sausville received his M.D. and Ph.D. in pharmacology from the Albert Einstein College of Medicine in the Bronx, N.Y. He completed his residency at Brigham and Women’s Hospital in Boston and a three-year fellowship in clinical oncology at NCI. He was an attending physician at the U.S. Naval Hospital in Bethesda and Georgetown University Hospital in Washington before returning to NCI, where he served as associate director of NCI’s Developmental Therapeutics Program for 10 years.